";s:4:"text";s:4244:" The most commonly observed adverse reactions were elevated hepatic enzymes (7.5%), increased alkaline phosphate (3.8%), and thrombocytosis (3.8%). On days 3 and 5 of the therapy, the success rate of meropenem was higher than that of comparatives (30% versus 17.6% on day 3, 50.0% versus 39.3% on day 5). [22] analyzed the distribution of carbapenem resistance mechanisms among Pseudomonas aeruginosa clinical isolates. No dose-depended differences were in half-life, distribution volume, clearance, or renal clearance among the doses studied. Clinical and bacterial response rates for meropenem were 100% for sepsis and 87.5% for nosocomial pneumoniae. In literature, there are no studies of meropenem metabolism in infants and children.In order to define meropenem dosing guidelines for children, an escalating, single-dose, pharmacokinetic study at 10, 20, and 40 mg/kg was performed by Blumer et al. [14] conducted a retrospective cohort study of 5,566 infants treated with meropenem or imipenem/cilastatin. The relationship between meropenem clearance and estimated creatinine was assessed by nonlinear regression. The most commonly reported adverse events were sepsis (6%), seizures (5%), elevated conjugated bilirubin (5%), and hypokalemia (5%). [12] compared the steady-state pharmacokinetics of meropenem given as a short (30 min) or prolonged (4 hours) infusion to very-low-birth-weight (gestational age < 32 weeks; birth weight < 1,200 grams) neonates to define the appropriate dosing regimen for a phase 3 efficacy study. [25] reported the isolation of clinical strains of Streptococcus mitis with unusually high MIC values for β-lactam compounds tested, only the carbapenems imipenem and meropenem showed MICs below 32 μg/ml. The incidence of drug-related adverse events (mostly slight increase in liver enzymes) was 8.5%. x��][�۸�~w���RR���d�5U�n���zw}N�� k.V2��#y]���ƍ A�$FNje�jth4�
�s������l�œ'�O������e�������:��������n�9���ųϋg�? Effectiveness was evaluable in 192 (96%) infants, and overall treatment success was 84%. Carbapenem clearance in neonates is low. Variability relates to maturation (weight, age) and renal function (creatinine clearance), while observations in neonates with renal failure are absent. Using chromosomal Streptococcus mitis DNA, the laboratory strain Streptococcus pneumoniae R6 could be transformed in four successive steps to cefotaxime and benzylpenicillin resistance of 64 μg/ml. Pacifici GM (2019) Clinical pharmacology of meropenem in infants and children. Meropenem - Neonatal Dose Adjustment Dose and frequency adjustment may be required in cases of impaired renal function. Renal Dosage Adjustment Guidelines for Antimicrobials The pharmacists will automatically adjust the doses of any of the antimicrobials included in the protocol according to the estimated creatinine clearance (generally using the Cockroft-Gault equation for patients ≥ 18 years old and the Schwartz equation for patients < 18 years old). Bʊ�? The adverse events were not related to meropenem.